Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.04
ANTH's Cash to Debt is ranked higher than
74% of the 926 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. ANTH: 2.04 )
ANTH' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 2.04

F-Score: 2
Z-Score: -28.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -247.09
ANTH's ROE (%) is ranked lower than
54% of the 895 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. ANTH: -247.09 )
ANTH' s 10-Year ROE (%) Range
Min: -582.71   Max: -179.7
Current: -247.09

-582.71
-179.7
ROA (%) -101.22
ANTH's ROA (%) is ranked lower than
53% of the 930 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.82 vs. ANTH: -101.22 )
ANTH' s 10-Year ROA (%) Range
Min: -254.43   Max: -94.5
Current: -101.22

-254.43
-94.5
ROC (Joel Greenblatt) (%) -4165.46
ANTH's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.02 vs. ANTH: -4165.46 )
ANTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -238386.67   Max: -2879.41
Current: -4165.46

-238386.67
-2879.41
EBITDA Growth (3Y)(%) -52.00
ANTH's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ANTH: -52.00 )
ANTH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -52
Current: -52

EPS Growth (3Y)(%) -50.70
ANTH's EPS Growth (3Y)(%) is ranked higher than
53% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. ANTH: -50.70 )
ANTH' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -50.7
Current: -50.7

» ANTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ANTH Guru Trades in Q1 2014

Jim Simons 97,400 sh (+46.03%)
Louis Moore Bacon 200,000 sh (-11.03%)
» More
Q2 2014

ANTH Guru Trades in Q2 2014

Jim Simons 124,899 sh (+28.23%)
Louis Moore Bacon 200,000 sh (unchged)
» More
Q3 2014

ANTH Guru Trades in Q3 2014

Louis Moore Bacon Sold Out
Jim Simons 26,700 sh (-78.62%)
» More
Q4 2014

ANTH Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ANTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 26.50
ANTH's P/B is ranked higher than
50% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. ANTH: 26.50 )
ANTH' s 10-Year P/B Range
Min: 0   Max: 27.3
Current: 26.5

0
27.3
EV-to-EBIT -3.61
ANTH's EV-to-EBIT is ranked higher than
51% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.09 vs. ANTH: -3.61 )
ANTH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.61

Current Ratio 1.84
ANTH's Current Ratio is ranked higher than
64% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.36 vs. ANTH: 1.84 )
ANTH' s 10-Year Current Ratio Range
Min: 0.15   Max: 16.1
Current: 1.84

0.15
16.1
Quick Ratio 1.84
ANTH's Quick Ratio is ranked higher than
72% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. ANTH: 1.84 )
ANTH' s 10-Year Quick Ratio Range
Min: 0.15   Max: 16.1
Current: 1.84

0.15
16.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 54.80
ANTH's Price/Net Cash is ranked higher than
85% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ANTH: 54.80 )
ANTH' s 10-Year Price/Net Cash Range
Min: 2.01   Max: 41.88
Current: 54.8

2.01
41.88
Price/Net Current Asset Value 54.80
ANTH's Price/Net Current Asset Value is ranked higher than
78% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ANTH: 54.80 )
ANTH' s 10-Year Price/Net Current Asset Value Range
Min: 2.01   Max: 41.88
Current: 54.8

2.01
41.88
Price/Tangible Book 25.90
ANTH's Price/Tangible Book is ranked higher than
54% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.29 vs. ANTH: 25.90 )
ANTH' s 10-Year Price/Tangible Book Range
Min: 1.96   Max: 14.46
Current: 25.9

1.96
14.46
Earnings Yield (Greenblatt) -27.70
ANTH's Earnings Yield (Greenblatt) is ranked lower than
52% of the 927 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ANTH: -27.70 )
ANTH' s 10-Year Earnings Yield (Greenblatt) Range
Min: -112.9   Max: 0
Current: -27.7

-112.9
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:6TA1.Germany,
Anthera Pharmaceuticals, Inc., was incorporated on September 9, 2004 in the state of Delaware. It is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases. The Company's product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells. Its product development program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which it believes current treatments are either inadequate or non-existent. It currently relies on contract manufacturers to produce drug substances and drug products required for its clinical studies under current Good Manufacturing Practice with oversight by its internal managers. The Company competes with pharmaceutical and more established biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK